Vedolizumab: New option for IBD patients

If conventional IBD treatments aren’t working, vedolizumab is an alternative. Therapeutic drug monitoring helps improve treatment success with vedolizumab.

Adalimumab monitoring improves therapy success

The drug adalimumab is used very successfully in the treatment of various inflammatory diseases. Yet in some patients, the efficacy of this drug decreases over time. We explain why this is so and [...]

World IBD Day: Five myths about inflammatory bowel diseases

May is completely characterized by intestinal health: first Digestive Disease Week, now World IBD Day. The aim of the IBD action day is to raise awareness about inflammatory bowel diseases [...]

Therapeutic drug monitoring: Greater efficiency through quick tests

Therapeutic drug monitoring (TDM) is used to measure the concentration of an active ingredient in the patient’s blood. Using this information, physicians can adjust the dose individually to the [...]

Better therapy, lower costs: Optimizing the treatment of IBD

So-called TNFα blockers are commonly used in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Therapeutic drug monitoring improves the effect of [...]

TNFalpha Blocker and Drug Monitoring

TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab (Remicade®, [...]

Calprotectin predicts relaps after stopping TNFα treatment

Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.

Drug Monitoring reduces Infliximab treatment costs

Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy. One common way of [...]

Drug Monitoring of Infliximab Biosimilars RemsimaTM and Inflectra®

Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars RemsimaTM and Inflectra® were equally well quantified as Remicade® (Infliximab, IFX) in their clinically validated [...]